RNAi Efficacy Against ALS (Lou Gehrig’s Disease) in a Research Model Published in Peer-Reviewed Journal; RXi Pharmaceuticals Exclusive Licensee of Research

WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a leading company in RNA targeting, today announced that RNA interference (RNAi) research findings based on intellectual property exclusively licensed to RXi has been published in the April 2008 issue of the peer-reviewed Journal of Biological Chemistry. The paper, "Therapeutic gene silencing delivered by a chemically modified siRNA against mutant SOD1 slows ALS progression", has been selected as a Journal of Biological Chemistry (JBC) Paper of the Week. Each week, JBC Editorial Board members and Editors select papers that rank in the top 1% of papers they will review in a year in significance and overall importance as Paper of the Week.
MORE ON THIS TOPIC